Daily FNArena News

A wrap of the day’s activity on the Australian stock market.

Most, but not all brokers anticipate a slight moderation in Chinese GDP growth next year as immediate policy tightening and longer term reform measures take effect.

McPherson’s is continuing to diversify its business and this is expected to deliver earnings growth in the next few years, according to Moelis.

The Chartist reports the technical signs suggest the Aussie dollar will again breach US90c and head back to previous lows.

PFP Wealth Management’s Tim Price looks for stock market value outside of the developed world.

A wrap of the day’s activity on the Australian stock market.

Moelis has taken a look at the portfolio of products waiting in the wings at Mayne Pharma and considers there is more upside for the stock.

Currently there’s pressure on laboratory services provider ALS but brokers are tuned to the potential upside.

Michael Gable of Fairmont Equities evaluates the technicals for WorleyParsons following the company’s shock profit warning and subsequent share price plunge.

As uranium miners across the globe defer or cut production, the uranium spot price has found some renewed hope.